Keywords: mixed, results, sanofi-aventis, insomnia, study, good, antidepressant

Mixed results for Sanofi-Aventis: insomnia study good, antidepressant faces setback

Article

Print This

French drug major Sanofi-Aventis has reported data from ongoing trials for three of its pipeline candidates. The GEMS and NOCTURNE ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in